Princeton Alpha Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Princeton Alpha Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,157	Closed	-$792K	–	714
2016 Q4	$792K	Buy	+2,157	New	+$820K	0.16%	205
2016 Q3	–	Sell	-1,897	Closed	-$662K	–	911
2016 Q2	$662K	Sell	1,897 -1,470	-44%	-$566K	0.12%	270
2016 Q1	$1.21M	Buy	+3,367	New	+$1.39M	0.2%	163
2015 Q4	–	Sell	-670	Closed	-$312K	–	891
2015 Q3	$312K	Buy	+670	New	+$360K	0.06%	459
2014 Q4	–	Sell	-3,894	Closed	-$1.4M	–	824
2014 Q3	$1.4M	Sell	3,894 -4,215	-52%	-$1.41M	0.32%	69
2014 Q2	$2.29M	Buy	+8,109	New	+$2.4M	0.47%	39

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Princeton Alpha Management's REGN Position: Q1 2017 in Review

Princeton Alpha Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 2,157 shares — an estimated $792K sold.

Princeton Alpha Management first reported a position in REGN in Q2 2014 and held it in 6 quarters. The position peaked at $2.29M in Q2 2014. 579 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

Princeton Alpha Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Princeton Alpha Management sold 2,157 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $792K.
Princeton Alpha Management first reported a position in Regeneron Pharmaceuticals in Q2 2014 and held it in 6 quarters.
Princeton Alpha Management's Regeneron Pharmaceuticals position peaked at $2.29M in Q2 2014.
579 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on Princeton Alpha Management's 13F filing for Q1 2017, filed 3 May 2017.